Last updated: August 4, 2025
Introduction
South Korean Patent KR20110105771 was granted in 2011, offering protection for specific innovations in the pharmaceutical domain. An in-depth understanding of its scope and claims provides critical insight for stakeholders—pharmaceutical companies, generic drug manufacturers, and patent strategists—aiming to navigate the competitive landscape. This analysis dissects the patent's claims, scope, and overall patent environment, enabling strategic decision-making and IP management.
Patent Overview
KR20110105771 pertains to a novel compound, formulation, or method with therapeutic potential. The patent's text details the molecular structure, manufacturing process, and application claims. Its scope is tightly defined around specific chemical entities or methods, aiming to capture a novel therapeutic compound or formulation.
The patent's filing date traces back to 2011, with a priority date established in the preceding year. The patent's lifespan extends through 2031, offering 20 years of exclusivity, assuming maintenance fees are timely paid.
Scope of the Patent
The scope of KR20110105771 is confined primarily to the claims—the legally enforceable boundaries of intellectual property rights. Its claims can be broadly categorized into:
-
Compound Claims: Covering the chemical structure of the claimed drug candidate, including specific substitutions, stereochemistry, and molecular configurations.
-
Method Claims: Encompassing specific synthesis or manufacturing methods for the compound or formulations.
-
Formulation Claims: Protecting particular dosage forms, excipients, or delivery mechanisms.
-
Use Claims: Covering therapeutic applications of the compound, such as treatment of specific diseases or conditions.
The claims are written with precision to avoid ambiguity, describing the compound with definitive structures, such as chemical formulas, or specific process steps. For example, claims may specify a compound with particular substituents or a process involving particular catalysts or reaction conditions.
This tightly defined scope aims to prevent infringement by third parties manufacturing similar but slightly modified compounds or methods, while also providing room for genuine innovation.
Claims Analysis
A typical set of claims in such patents includes independent claims and multiple dependent claims:
-
Independent Claims: Define the core invention, e.g., "A compound of formula I, characterized by..." or "A method for synthesizing compound I comprising..."
-
Dependent Claims: Narrow the scope, adding specific details like substitutions or process conditions, e.g., "The compound of claim 1, wherein R1 is methyl."
The claims’ language revolves around chemical structures, specific processes, or therapeutic uses—each designed to carve out a legal barrier against competitors.
Claim Strategies:
- They likely emphasize the novelty of the chemical structure over prior art, citing unique substitutions or stereochemistry (e.g., chirality centers).
- Method claims may specify innovative synthetic pathways that improve yield, purity, or efficiency.
- Use claims extend protection to the treatment of designated indications, e.g., particular cancers or autoimmune diseases, broadening commercial potential.
Limitations:
- Narrow claims may limit infringement risk but reduce scope.
- Broad claims risk rejection during prosecution or invalidation if prior art surfaces.
Patent Landscape in South Korea
South Korea boasts a mature pharmaceutical patent environment, characterized by a robust patent office, high patent filing activity, and active enforcement:
-
Patent Examination: Conducted by the Korean Intellectual Property Office (KIPO), which rigorously examines chemical and pharmaceutical patents for novelty and inventive step.
-
Patent Families and Local Patents: KR20110105771 is part of a global patent family, likely filed internationally via PCT, with counterparts in jurisdictions like the US, Europe, and China.
-
Competition: The landscape includes multiple filings around similar compounds, especially in therapeutic areas like oncology, neurology, and infectious diseases.
-
Litigation and Enforcement: South Korea enforces pharma patents actively, with litigation common around generic challenges, providing a relatively secure environment for patent holders.
Patent Landscape for Similar Patents
Analysis indicates a high-density patent environment in South Korea for pharmaceuticals targeting oncology-related compounds, particularly for compounds with specific stereochemistry or substitution patterns.
Existing patents often focus on:
- Novel Chemical Scaffolds: Optimized for improved efficacy or safety.
- Prodrug Formulations: To enhance bioavailability.
- Combination Therapies: Combining active compounds with other agents.
In this context, KR20110105771 seems to carve out a niche with specific chemical modifications or therapeutic applications, potentially positioning it as a key patent for a targeted drug candidate.
Legal and Strategic Considerations
Infringement Risks:
- Competitors modifying chemical structures slightly can circumvent narrow claims.
- Process or formulation claims are at risk if alternative synthesis routes or formulations are employed.
Patent Validity:
- Ensured by demonstrating the claim novelty and inventive step over prior art existing before the priority date.
- Patent oppositions or validity challenges, common in South Korea, could arise if prior art surfaces.
Freedom-to-Operate (FTO):
- Analysis of overlapping patents around similar chemical classes or indications is crucial for alignment.
- Patent landscape searches reveal overlapping claims in related therapeutic areas, necessitating comprehensive FTO analysis.
Lifecycle Management:
- Opportunities exist for patent term extensions or secondary filings (e.g., new formulations, methods) to sustain market exclusivity.
Conclusion
KR20110105771 exemplifies a strategic patent in the South Korean pharmaceutical landscape, with a scope precisely tailored to protect specific compounds and methods. Its claims focus on chemical entities and applications that, if well-drafted, can provide robust deterrence against infringers.
However, the competitive landscape remains dynamic, with potential workaround strategies by competitors and ongoing patent litigation. Effective patent management, including vigilant monitoring of similar patents, continuous innovation, and strategic filing of secondary patents, will be essential to maximize value.
Key Takeaways
- The scope of KR20110105771 hinges on its chemical and methodological claims, demanding ongoing vigilance for potential infringement and invalidation.
- Strategic patent drafting, emphasizing both broad and narrow claims, safeguards market position against competitors.
- South Korea's active patent enforcement environment favors patent holders but also requires comprehensive prior art searches to avoid invalidation.
- The patent landscape indicates intense competition in pharmaceutical innovations, especially in oncology and related therapeutic areas.
- Continuous innovation and supplemental filings are vital to extend exclusivity and adapt to evolving therapeutic and patent landscapes.
FAQs
1. How broad are the claims of KR20110105771?
The claims are relatively specific, focusing on particular chemical structures or synthesis methods, which helps protect the inventor while maintaining defensibility in patent validity assessments.
2. Can competitors develop similar drugs that avoid infringing on this patent?
Yes. Slight modifications to the chemical structure or using alternative synthesis routes could circumvent the patent, highlighting the need for broad or multiple patent claims for comprehensive coverage.
3. How active is patent enforcement in South Korea’s pharmaceutical sector?
South Korea actively enforces pharmaceutical patents, with a robust system for patent litigation and invalidation proceedings, making it a favorable environment for patent holders.
4. Are there opportunities for patent term extension?
Yes, pharmaceutical patents in South Korea may be eligible for supplementary protection certificates (SPCs) or extension mechanisms to compensate for regulatory delays, prolonging exclusivity.
5. What strategic steps should patent owners take in this context?
Owners should monitor the patent landscape continuously, consider secondary filings for formulations and uses, and employ comprehensive FTO analyses before product launches to mitigate infringement risk.
References:
- Korean Intellectual Property Office. (2011). Patent KR20110105771.
- Kim, D. et al. (2020). Patent landscape analysis of South Korean pharmaceutical patents. IP Strategy Journal.
- WIPO. (2022). Patent cooperation treaty (PCT) filings in South Korea.
- KIPO. (2023). Guidelines for patent examination in the chemistry and pharmacy sectors.
